Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 3
2017 2
2018 4
2019 3
2020 5
2021 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes.
Kizhakeyil A, Zaini NBM, Poh ZS, Wong BHS, Loh X, Ng AS, Low ZS, Prasannan P, Gong C, Tan MGK, Nagarajan C, Huang D, Lu PW, Lim JQ, Barrans S, Ong CK, Lim ST, Chng WJ, Follows G, Hodson DJ, Du MQ, Goh YT, Tan SH, Grigoropoulos NF, Verma NK. Kizhakeyil A, et al. Mol Cancer. 2021 Oct 16;20(1):134. doi: 10.1186/s12943-021-01437-0. Mol Cancer. 2021. PMID: 34654425 Free PMC article. No abstract available.
Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis.
Gong C, Krupka JA, Gao J, Grigoropoulos NF, Giotopoulos G, Asby R, Screen M, Usheva Z, Cucco F, Barrans S, Painter D, Zaini NBM, Haupl B, Bornelöv S, Ruiz De Los Mozos I, Meng W, Zhou P, Blain AE, Forde S, Matthews J, Khim Tan MG, Burke GAA, Sze SK, Beer P, Burton C, Campbell P, Rand V, Turner SD, Ule J, Roman E, Tooze R, Oellerich T, Huntly BJ, Turner M, Du MQ, Samarajiwa SA, Hodson DJ. Gong C, et al. Mol Cell. 2021 Oct 7;81(19):4059-4075.e11. doi: 10.1016/j.molcel.2021.07.041. Epub 2021 Aug 25. Mol Cell. 2021. PMID: 34437837 Free article.
Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma.
Morschhauser F, Dyer MJS, Walter HS, Danilov AV, Ysebaert L, Hodson DJ, Fegan C, Rule SA, Radford J, Cartron G, Bouabdallah K, Davies AJ, Spurgeon S, Rajakumaraswamy N, Li B, Humeniuk R, Huang X, Bhargava P, Jürgensmeier JM, Salles G. Morschhauser F, et al. Leukemia. 2021 Jul;35(7):2108-2113. doi: 10.1038/s41375-020-01108-x. Epub 2020 Dec 17. Leukemia. 2021. PMID: 33328591 Free PMC article. Clinical Trial. No abstract available.
PI3Kδ inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax.
Serrat N, Guerrero-Hernández M, Matas-Céspedes A, Yahiaoui A, Valero JG, Nadeu F, Clot G, Di Re M, Corbera-Bellalta M, Magnano L, Rivas-Delgado A, Enjuanes A, Beà S, Cid MC, Campo E, Montero J, Hodson DJ, López-Guillermo A, Colomer D, Tannheimer S, Pérez-Galán P. Serrat N, et al. Blood Adv. 2020 Sep 8;4(17):4217-4231. doi: 10.1182/bloodadvances.2020001584. Blood Adv. 2020. PMID: 32898249 Free PMC article.
21 results